Boston Scientific Corporation (NYSE:BSX) announced on January 12, 2026, that it has entered into a definitive agreement to acquire Valencia Technologies. This acquisition will expand the company's Urology franchise into implantable tibial nerve stimulation (ITNS) through the FDA-approved eCoin System.
The eCoin device is a coin-sized, minimally invasive implant. It is designed for the treatment of overactive bladder, a condition affecting nearly 30 million U.S. adults over the age of 40 who experience bothersome symptoms. According to the company, only 19% of these adults currently receive treatment beyond lifestyle adjustments.
In a pivotal clinical trial for the eCoin System, 68% of patients recorded at least a 50% reduction in urge urinary incontinence episodes. The company stated that the acquisition addresses patients who are refractory to or intolerant of conservative therapies. Management described ITNS as a high-growth adjacency that reinforces the company's organic growth potential.
Separately, on January 9, 2026, Goldman Sachs issued an update on Boston Scientific. The firm lowered its price target on the stock from $124 to $112 while reiterating a 'Buy' rating. According to a report from TheFly, Goldman Sachs expects investor attention to refocus on organic growth in 2026 as valuations and fundamentals normalize.
Boston Scientific Corporation develops and markets interventional medical devices across its MedSurg and Cardiovascular segments.